Thymosin Alpha-1 (Thymalfasin) — The Sunlight Experiment

What Is Thymosin Alpha-1?

Thymosin alpha-1 (thymalfasin, brand name Zadaxin) is a synthetic 28-amino-acid peptide corresponding to a fragment of the naturally occurring thymic hormone prothymosin alpha, used clinically as an immunomodulator. Unlike most peptides marketed to biohackers, it is an actual approved drug in more than 30 countries — indicated for chronic hepatitis B, used as a vaccine adjuvant, and studied as add-on therapy in sepsis and cancer. It is not approved as a drug in the United States and is not an approved dietary supplement anywhere. Its broad immune-restoring reputation rests on a genuine but mixed clinical evidence base.

Evidence

The clearest human data are in critical care. In the ETASS trial — a multicentre, single-blind, randomised controlled trial in patients with severe sepsis — thymosin alpha-1 added to conventional therapy was associated with improved outcomes versus control ^{1Reference 1Wu J et al et al. · 2013RCTThe efficacy of thymosin alpha 1 for severe sepsis (ETASS): a multicenter, single-blind, randomized and controlled trial — randomised/RCTView study →}. A systematic review of randomised controlled trials in sepsis found an overall mortality benefit but flagged heterogeneity and the need for larger, higher-quality studies ^{2Reference 2Li C et al et al. · 2015Systematic reviewThe efficacy of thymosin alpha 1 as immunomodulatory treatment for sepsis: a systematic review of randomized controlled trials — systematic reviewView study →}; a subsequent large multicentre trial (TESTS) did not show a clear mortality reduction, so the sepsis picture is genuinely unsettled. Thymosin alpha-1 is also approved for chronic hepatitis B on the basis of randomised trials showing improved virological response, which underpins its regulatory approvals abroad. Broader anti-ageing, general “immune-boosting” and cancer-cure claims common in peptide marketing go well beyond what these trials establish, and I did not find high-quality trials supporting those uses in this quick pass.

Dosage & Safety

Clinical dosing (e.g. 1.6 mg subcutaneously twice weekly for hepatitis B, or higher frequencies in ICU sepsis protocols) comes from trials and regulatory labels and is not a personal recommendation. Thymosin alpha-1 was generally well tolerated in the trials cited ^{1Reference 1Wu J et al et al. · 2013RCTThe efficacy of thymosin alpha 1 for severe sepsis (ETASS): a multicenter, single-blind, randomized and controlled trial — randomised/RCTView study →}^{2Reference 2Li C et al et al. · 2015Systematic reviewThe efficacy of thymosin alpha 1 as immunomodulatory treatment for sepsis: a systematic review of randomized controlled trials — systematic reviewView study →}, but its safety outside supervised clinical use — including drug interactions, long-term use, and pregnancy — is not established here. It is a prescription immunomodulator (approved in some countries, not the US) and not an approved dietary supplement; grey-market “research peptide” material is unregulated and of unverified purity. Everything here is informational only.

References

Wu J et al. (2013). The efficacy of thymosin alpha 1 for severe sepsis (ETASS): a multicenter, single-blind, randomized and controlled trial — randomised/RCT. Critical Care. https://pubmed.ncbi.nlm.nih.gov/23327199/
Li C et al. (2015). The efficacy of thymosin alpha 1 as immunomodulatory treatment for sepsis: a systematic review of randomized controlled trials — systematic review. BMC Infect Dis. https://pmc.ncbi.nlm.nih.gov/articles/PMC5025565/